Empowered Funds LLC Buys New Position in Edwards Lifesciences Corporation $EW

Key Points

• Empowered Funds LLC initiated a position in Edwards Lifesciences during the second quarter, purchasing 43,120 shares valued at approximately $3.9 million. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences reported quarterly earnings of $0.78 per share, exceeding the $0.74 consensus estimate, while revenue rose 13.6% year over year to $1.74 billion. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus rating and an average price target of $100.27, compared with the stock’s reported price of $90.78. Company insiders sold 5,045 shares worth roughly $457,749 during the last quarter.

Empowered Funds LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 43,120 shares of the medical research company's stock, valued at approximately $3,901,000.

A number of other hedge funds have also added to or reduced their stakes in EW. United Capital Financial Advisors LLC bought a new position in Edwards Lifesciences during the second quarter worth $1,807,000. Old North State Trust LLC bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $278,000. Equitable Holdings Inc. bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $860,000. Jefferies Financial Group Inc. acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $3,584,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $16,823,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 544 shares of the company's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Annette Bruls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company's stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,045 shares of company stock worth $457,749 in the last quarter. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW opened at $90.78 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock has a 50 day moving average price of $89.71 and a two-hundred day moving average price of $85.26. The firm has a market capitalization of $52.27 billion, a P/E ratio of 52.17, a P/E/G ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company's revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several recent research reports. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Evercore restated an "outperform" rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Citigroup increased their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source